Primary central nervous system lymphoma (PCNSL) is an extranodal variant of non-Hodgkin lymphoma (NHL) that is confined to the nervous system. The diagnostic and therapeutic approaches to PCNSL are different from those that are applied to other forms of NHL or to other brain cancers. The International Primary Central Nervous System Lymphoma Collaborative Group (IPCG) consists of specialists from multiple countries and disciplines dedicated to the study of PCNSL. The IPCG holds an annual scientific conference at the American Society of Hematology meeting in which various research topics related to PCNSL are discussed. An international expert on the topic under discussion is selected each year by an executive committee to chair the scientific conference. These meetings have led to multiple collaborative projects that have positively impacted the field and that have been published in the peer- reviewed literature. The annual IPCG meeting is a critical forum for generating new ideas and approaches to this unique form of brain cancer and lymphoma. The 2014 conference topic is IPCG Evaluation and Response Criteria for Primary CNS Lymphoma for use in clinical practice and in clinical trials.
The International Primary Central Nervous System Lymphoma (PCNSL) Collaborative Group (IPCG) holds an annual scientific conference each year to review research progress on PCNSL, a type of non-Hodgkin lymphoma. The annual conference has been very successful in stimulating international collaboration among the many different specialists involved in the treatment of this rare type of lymphoma. The 2014 conference theme is to review and revise the 2005 IPCG Evaluation and Response Criteria for Primary CNS Lymphoma.
|Han, Catherine H; Batchelor, Tracy T (2017) Primary Central Nervous System Lymphoma. Continuum (Minneap Minn) 23:1601-1618|
|Kasenda, B; Ferreri, A J M; Marturano, E et al. (2015) First-line treatment and outcome of elderly patients with primary central nervous system lymphoma (PCNSL)--a systematic review and individual patient data meta-analysis. Ann Oncol 26:1305-13|
|Batchelor, Tracy T; Reardon, David A; de Groot, John F et al. (2014) Antiangiogenic therapy for glioblastoma: current status and future prospects. Clin Cancer Res 20:5612-9|
|Flannick, Jason; Thorleifsson, Gudmar; Beer, Nicola L et al. (2014) Loss-of-function mutations in SLC30A8 protect against type 2 diabetes. Nat Genet 46:357-63|
|Ponzoni, M; Issa, S; Batchelor, T T et al. (2014) Beyond high-dose methotrexate and brain radiotherapy: novel targets and agents for primary CNS lymphoma. Ann Oncol 25:316-22|
|Taylor, Jennie W; Flanagan, Eoin P; O'Neill, Brian P et al. (2013) Primary leptomeningeal lymphoma: International Primary CNS Lymphoma Collaborative Group report. Neurology 81:1690-6|
|Ferreri, Andrés J M; Zucca, Emanuele; Armitage, James et al. (2013) Ten years of international primary CNS lymphoma collaborative group studies. J Clin Oncol 31:3444-5|
|Abla, Oussama; Weitzman, Sheila; Blay, Jean-Yves et al. (2011) Primary CNS lymphoma in children and adolescents: a descriptive analysis from the International Primary CNS Lymphoma Collaborative Group (IPCG). Clin Cancer Res 17:346-52|
|Patrij, Katrin; Reiser, Marcel; Wätzel, Luise et al. (2011) Isolated central nervous system relapse of systemic lymphoma (SCNSL): clinical features and outcome of a retrospective analysis. Ger Med Sci 9:Doc11|
|Chan, Chi-Chao; Rubenstein, James L; Coupland, Sarah E et al. (2011) Primary vitreoretinal lymphoma: a report from an International Primary Central Nervous System Lymphoma Collaborative Group symposium. Oncologist 16:1589-99|
Showing the most recent 10 out of 13 publications